[1] World Health Organization.COVID-19 weekly epidemiological update[EB/OL]. (2022-06-05).https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-8-june-2022.
[2] 中华预防医学会新型冠状病毒肺炎防控专家组.新型冠状病毒肺炎流行病学特征的最新认识[J]. 中华流行病学杂志,2020,41(2):139-144.
[3] CIACCIOM,AGNELLO L. Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)[J]. Diagnosis, 2020, 7(4):365-372.
[4] ROY S, GHOSH P. Factors affecting COVID-19 infected and death rates inform lockdown-related policymaking[J]. PLoS One, 2020, 15(10):e0241165.
[5] 谭远发, 王乐, 黄建忠. 新冠肺炎死亡率的国际差异及其影响因素—基于年龄结构和检测率的双重视角[J]. 人口研究,2021,45(2):30-46.
[6] BERNERO E, RUIZ L A, ESPAÑA P P, et al. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences[J]. Infection,2022,50(1):179-189.
[7] BREIJYEH Z, KARAMAN R. Comprehensive review on Alzheimer’s disease: causes and treatment[J]. Molecules,2020,25(24):5789.
[8] Alzheimer’s Disease International, McGill University.World Alzheimer report 2021: journey through the diagnosis of dementia[R/OL]. (2021-09-21).https://www.alzint.org/resource/world-alzheimer-report-2021/.
[9] LIANG C S, LI D J, YANG F C, et al. Mortality rates in Alzheimer’s disease and non-Alzheimer’s dementias: a systematic review and meta-analysis[J]. Lancet Health Longev,2021,2(8):e479-e488.
[10] HAIDAR M A, SHAKKOUR Z, RESLAN M A, et al. SARS-CoV-2 involvementin central nervous system tissue damage[J]. Neural Regen Res, 2022, 17(6):1228-1239.
[11] CIACCIO M, LO SASSO B, SCAZZONE C, et al. COVID-19 and Alzheimer’s disease[J]. Brain Sci,2021,11(3):305.
[12] BERGER J R.COVID-19 and the nervous system[J]. J Neurovirol, 2020, 26:143-148.
[13] 闵瑞,刘洁,代喆,等.新型冠状病毒肺炎发病机制及临床研究进展[J]. 中华医院感染学杂志,2020,30(8):1171-1176.
[14] 陈庆华,张凤强,李立新,等.阿尔茨海默病发病机制和诊断技术研究进展[J]. 中华老年心脑血管病杂志,2018,20(1):108-110.
[15] 简晔,刘文锋,袁顺灵.脂联素在运动调节自噬并缓解阿尔茨海默病过程中的效应及机制[J]. 中国病理生理杂志,2022,38(1):154-161.
[16] HASCUP E R, HASCUP K N.Does SARS-CoV-2 infection cause chronic neurological complications?[J]. Geroscience, 2020, 42(4):1083-1087.
[17] AKIYAMA H, BARGER S, BARNUM S, et al. Inflammation and Alzheimer’s disease[J]. Neurobiol Aging, 2020, 21(3):383-421.
[18] MCLOUGHLIN B C, MILES A, WEBB T E,et al. Functional and cognitive outcomes after COVID-19 delirium[J]. Eur Geriatr Med, 2020, 11(5):857-862.
[19] BEKTAS A, SCHURMAN S H, FRANCESCHI C, et al. A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS,cytokine storm syndrome, and post-ICU syndrome accelerate short-and long-term inflammaging?[J]. Immun Ageing,2020,17:23.
[20] AMERES M, BRANDSTETTER S, TONCHEVA A A, et al. Association of neuronal injuryblood marker neurofilament light chain with mild-to-moderate COVID-19[J]. J Neurol, 2020,267(12):3476-3478.
[21] COOPER J, STUKAS S, HOILAND R L, et al. Quantification of neurological blood-based biomarkers in critically ill patients with coronavirus disease 2019[J]. Crit Care Explor, 2020,2(10):e0238.
[22] KUO C L, PILLING L C, ATKINS J L, et al. ApoE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort[J]. J Gerontol A Biol Sci Med Sci, 2020,75(11):2231-2232.
[23] STRAFELLA C, CAPUTOV, TERMINE A, et al. Investigation of geneticvariations of IL6 and IL6R as potential prognostic and pharmacogenetics biomarkers: implications for COVID-19 and neuroinflammatory disorders[J]. Life: Basel, 2020, 10(12):351.
[24] SIMONE M J, TAN Z S. The role of inflammation in the pathogenesis of delirium and dementia in older adults: a review[J]. CNS Neurosci Ther, 2011, 17(5):506-513.
[25] GARCIA-REVILLA J, DEIERBORG T, VENERO J L, et al. Hyperinflammation and fibrosis in severe COVID-19 patients: galectin-3, a target molecule to consider[J]. Front Immunol, 2020, 11:2069. |
